Comparative-effectiveness data was available for only about half of new drugs approved by the Food and Drug Administration during the past 10 years. That's according to a new study, published in the May 4 issue of the Journal of the American Medical Association, which examined data about alternative treatment options available at the time of drugs' approval.
Many drugs lacked comparative-effectiveness data at time of approval
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.